FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

21 letters match. Newest first.

  1. Amgen Inc.

    FDA says an Amgen promotional video for the cancer drug Vectibix is false and misleading because it leaves out all risk information.

    Medium
  2. Ketdaxandrugs / www.ketdaxandrugs.org

    FDA warned Ketdaxandrugs it sells unapproved, misbranded ketamine "KETAMINE CRYSTAL" online without prescriptions to U.S. consumers.

    High risk
  3. Dermacare dba Filler Outlet

    South Korea's Dermacare, doing business as Filler Outlet, sells unapproved, misbranded injectable botulinum toxin to U.S. consumers through its website.

    High risk
  4. CelestaPro

    FDA told CelestaPro its website sells unapproved, misbranded injectable botulinum toxin drugs, including "Nabota 200 Unit", to U.S. consumers.

    High risk
  5. Aytu Biopharma

    FDA says Aytu Biopharma’s sponsored links for ADHD drug Cotempla XR-ODT are false or misleading and misbrand it.

    High risk
  6. Aytu Biopharma

    FDA warned Aytu Biopharma that sponsored links for ADHD drug Adzenys XR-ODT are false or misleading because they omit risk information.

    High risk
  7. Alora Pharmaceuticals

    FDA says Alora's paid search ads for RELEXXII ADHD drug are false or misleading because they omit risk information.

    Low
  8. CSL Behring

    FDA says CSL Behring's HIZENTRA TV ad overstates protection and plays down risks, misbranding the immune globulin biologic.

    Medium
  9. Eli Lilly and Company

    FDA says Eli Lilly’s Oprah-linked video for Zepbound and Mounjaro misled on serious risks.

    High risk
  10. Novo Nordisk Inc.

    FDA says Novo Nordisk’s Oprah Winfrey video makes Wegovy, Ozempic and Victoza look safer than their labels allow.

    High risk
  11. Eli Lilly and Company

    FDA says Eli Lilly's Zepbound online video omitted risk and limitations information and was not submitted to FDA.

    High risk
  12. Eli Lilly and Company

    FDA says Eli Lilly's sponsored Zepbound video omitted risk and use information, misbranding the drug.

    Low
  13. Sprout Pharmaceuticals, Inc.

    FDA warned Sprout Pharmaceuticals that a CEO Instagram post for Addyi omitted risks and indication limits.

    High risk
  14. Aurora Pharmaceutical

    FDA told Aurora Pharmaceutical its websites and brochures for three animal drugs hid safety warnings, making the products misbranded.

    Medium
  15. Elanco Animal Health

    FDA says Elanco's Zenrelia promotional materials omit or misstate safety warnings and study results, misbranding the veterinary drug.

    High risk
  16. Ozempen.com

    FDA warned Ozempen.com it sells unapproved, misbranded semaglutide pens to U.S. consumers online.

    High risk
  17. www.dashpct.com

    FDA warned www.dashpct.com over selling unapproved semaglutide drugs with unlawful labeling to U.S. consumers online.

    High risk
  18. Boehringer Ingelheim Animal Health USA

    FDA warned Boehringer Ingelheim Animal Health USA that Senvelgo promotional materials falsely claimed safety and effectiveness in previously insulin-treated cats.

    High risk
  19. ElectRx and Health Solutions, LLC

    ElectRx causes introduction of unapproved and misbranded prescription drugs into interstate commerce by substituting foreign-sourced drugs for FDA-approved prescriptions.

    High risk
  20. globalpharmacyplus.com

    FDA warned globalpharmacyplus.com in Canada for selling unapproved and misbranded prescription drugs to U.S. consumers online.

    High risk
  21. AcelRx Pharmaceuticals, Inc.

    FDA says AcelRx's DSUVIA banner and display ads misbrand the opioid tablet by oversimplifying dosing and understating risks.

    High risk